Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group.
Roos I, et al. Among authors: kuhle j.
JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625.
JAMA Neurol. 2023.
PMID: 37307006
Free PMC article.